A therapy that European regulators approved for treating Lambert-Eaton myasthenic syndrome (LEMS) can help manage myasthenia gravis symptoms, a study reports.
The findings on Firdapse appeared in the Journal of Clinical Neuroscience. The title of the article is “3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.”
Myasthenia gravis and LEMS are autoimmune disorders that share a common cause — abnormal interaction between nerve cells and muscles. This is due to overproduction and accumulation of antibodies that block communication signals.
Doctors can often distinguish between the two disorders. One reason is that in many cases, they have different manifestations. They also respond differently to stimulation and to cholinesterase inhibitors — a standard treatment for muscle disorders.
But some patients have characteristics of both diseases, posing a diagnostic and treatment challenge.